Product No | EMEA/H/C/004759 |
---|---|
Brand Name | Skyrizi |
Nonproprietary Name | risankizumab |
API | Risankizumab |
ATC Code | L04AC18 |
Indications | Plaque PsoriasisSkyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic ArthritisSkyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Crohn's diseaseSkyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. |
Orphan Drug | no |
Generics | no |
Marketing Authorization Holder | AbbVie Deutschland GmbH & Co. KG |
Status | Authorised(授权) |
Authorization Date | 2019-04-26 |
Version | 15 |
Condition Approval | no |
Exceptions | no |
Biosimilar | no |
Details | 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息) |
Extended Information